Zimmer Biomet (NYSE:ZBH – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, Wall Street Zen reports.
Several other research analysts have also recently weighed in on the stock. BMO Capital Markets reissued a “market perform” rating on shares of Zimmer Biomet in a report on Monday, September 28th. Citigroup raised their price objective on shares of Zimmer Biomet from $99.00 to $117.00 and gave the stock a “neutral” rating in a research report on Thursday, November 5th. Truist Financial set a $114.00 price objective on Zimmer Biomet in a report on Thursday, November 5th. Canaccord Genuity Group upped their target price on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research report on Monday, August 10th. Finally, Sanford C. Bernstein increased their target price on Zimmer Biomet from $93.00 to $107.00 and gave the stock a “market perform” rating in a research note on Thursday, November 5th. Seven equities research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $112.74.
View Our Latest Stock Report on ZBH
Zimmer Biomet Trading Down 0.0%
Shares of NYSE:ZBH opened at $103.18 on Friday. Zimmer Biomet has a 52-week low of $79.12 and a 52-week high of $112.54. The company has a market capitalization of $19.53 billion, a P/E ratio of 26.12, a price-to-earnings-growth ratio of 2.42 and a beta of 0.50. The company has a 50-day simple moving average of $95.76 and a 200 day simple moving average of $92.57. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.79 and a current ratio of 1.46.
Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 8.95% and a return on equity of 13.02%. The firm had revenue of $2.06 billion during the quarter, compared to analysts’ expectations of $2.04 billion. During the same period in the previous year, the business posted $1.90 earnings per share. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. Sell-side analysts forecast that Zimmer Biomet will post 8.56 earnings per share for the current year.
Insiders Place Their Bets
In other Zimmer Biomet news, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction on Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Chad Phipps sold 3,000 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the sale, the insider owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. The trade was a 4.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.28% of the stock is owned by company insiders.
Institutional Investors Weigh In On Zimmer Biomet
Institutional investors and hedge funds have recently bought and sold shares of the company. Tacita Capital Inc bought a new position in Zimmer Biomet in the 2nd quarter valued at about $26,000. Ancora Advisors LLC acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at approximately $29,000. Elevation Wealth Partners LLC raised its position in shares of Zimmer Biomet by 145.9% in the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 229 shares in the last quarter. Cassaday & Co Wealth Management LLC bought a new stake in shares of Zimmer Biomet during the 1st quarter worth approximately $44,000. Finally, Parvin Asset Management LLC bought a new stake in shares of Zimmer Biomet during the 2nd quarter worth approximately $47,000. Institutional investors own 88.89% of the company’s stock.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.
See Also
- Five stocks we like better than Zimmer Biomet
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
